Drug Discovery and Development

The advent of CRISPR as a gene editing tool appears to have revolutionized drug discovery and development in a very short time. CRISPR-Cas9 technology is also being utilized to target HIV, to mutate or cut out the provirus. Read about what’s new in potential treatments for HIV and the challenges facing the industry.

On the scientific horizon are possibilities of curing genetic disorders and altering disease management — all because of CRISPR. Investigating exciting approaches to reversing the effects of muscular dystrophy with the help of CRISPR is Dr. Chengzu Long at NYU. Read more about his life, his work, and where he sees CRISPR going next.

In this podcast, biosimilar key opinion leader Dr. Paul Rhyne provides an overview of the current state of biosimilars and their global impact. Leveraging his 20+ years of experience in developing biologics, he discusses how cost and patient access play a big role in this new field of research.

It is hoped that the development of biosimilars will lead to more accessible and cost-effective treatment options. Here we explore the current opportunities for biosimilars in rheumatoid arthritis and discuss the opportunities and concerns tied to their use.

Biosimilars are gaining in popularity and estimates predict that the U.S. could save between $40–250 billion in healthcare costs over the next decade by switching from biologics to biosimilars. See how biosimilars have gained in popularity recently, the challenges the U.S. faces in developing them, and what the future holds.

Cancer kills eight million people annually worldwide; this number will increase to 13 million by 2020. Lung, breast, colorectal, and prostate cancer are the four most commonly diagnosed cancers. Meaningful developments in immuno-oncology, or cancer immunotherapy, treatments are important now more than ever. Learn about some of the newer immunotherapies, including BiTE Antibodies and vaccines, and the companies developing them.

Immunotherapy is not a new concept; it has, in fact, been around for more than 125 years. However, recent scientific advances have led to the emergence and rapid evolution of the field, especially immuno-oncology. Get an introduction to this exciting emerging field, learn about the different personalized therapies currently available, and see what the future of cancer immunotherapy looks like.

The power to edit a gene is the power to change its function, and with it the biology of a cell. From generating novel cell lines and better animal models for the discovery and preclinical phases of therapeutic research to actually creating a therapeutic itself, CRISPR gene editing is allowing science to advance rapidly. See how enrichment and cell sorting can help generate edited cells faster and more reliably.

In this podcast, biosimilar expert, Amanda Turner, provides an in-depth explanation of the various in vitro assays used in biosimilar development and the importance of choosing the right assay type and components to achieve success.

Biomarker intelligence comes from understanding the biomarker landscape, that is, the characteristics and features of biomarkers, and disease pathways. This understanding, in turn, helps to recognize the utility of biomarkers. In this study, we partnered with Amplion Inc., to investigate biomarker usage in 24 immunotherapy companies. We found the most popular biomarkers and learnt how they are being used by each company.